Bio-Sustainable Future Enterprises Media (BSFA)
BSFA Share
BSFA Share
BSFA Share
BSFA Share
BSFA
BSFA Share
BSFA Level 2
BSFA Live
BSFA Broker
BSFA Directors
BSFA Financial
BSFA
BSFA Short
BSFA
BSFA Company
BSFA Company
BSFA Company
Last checked at -
Emily Telford, Project Manager of BSF Enterprise’s ( BSFA ) Lab Grown Leather, tells us about the science behind its product and why it has the potential to be even better than the real thing. Am...
Sarah Greenhalgh, MD and co-founder of BSF Enterprise ( LON:BSFA ) wholly owned subsidiary Kerato , on how the tissue engineering specialist is commercialising its cutting-edge corneal regeneratio...
"We are making strong progress, focusing our activities on several near-term commercial opportunities across a range of disciplines within our business. This has led to discussions of increasing qua...
Marcelo Bravo, Chief Business Officer at BSF Enterprise PLC ( LSE: BSFA ), (OTCQB: BSFAF) , the UK listed tissue-engineering biotech company, sits down with focus IR to talk through their latest ach...
Portfolio Update from BSF Enterprise ( BSFA ) highlights the operational progress across the operating subsidiaries targeting a variety of large end markets for their Tissue Engineering IP. ...
Here's what BSF Enterprise ( BSFA ) have been up to this year from a sample agreement with a multinational leather fashion house to engaging with a renowned French luxury brand. ...
BSF the Main Market listed biotech company and owner of corneal tissue replacement company Kerato Ltd, is pleased to announce that Kerato Ltd has entered into a Heads of Terms agreement and resea...
Which companies are benefitting from post election promises, who is picking up the handbag at Mulberry ( MUL ) and is lab grown leather just as resilient? Sarah talks high ethical fashion, cr...
Wholly owned subsidiary, 3D Bio-Tissues (3DBT), has launched its 'tissue-engineered skin'; grown solely from cells for use in the luxury leather goods market. ...
Option Awards - Total 2,400,000 options - To employees of BSFE and its wholly owned subsidiaries - 2.23% of current issued capital - Exercisable at 15p per share - Vesting: - 1,650,000 2n...
First Grant Funding - Collaboration between 3DBT and Newcastle University - Develop cost effective, ethical and sustainable ocular toxicity model - To reduces reliance on animal testing for n...
Sign In
Last checked at 
Follow the stocks
